Post by Parkinson's Insights

In a highly anticipated medical milestone published in Nature Medicine, the international STEM-PD clinical trial—led by world-renowned experts including Professor Roger A. (University of Cambridge) and Professor Malin Parmar (Lund University)—has taken a massive step toward potentially reversing Parkinson’s disease rather than just managing its symptoms. Here is everything you need to know about this groundbreaking trial: 🧠 The Goal: Parkinson’s destroys the specific brain cells that produce dopamine (the chemical that allows us to move smoothly). The STEM-PD trial used human embryonic stem cells, carefully coached in a lab to become young dopamine cells, and transplanted them directly into the brain to replace what was lost. 🇸🇪 A European First: This represents the very first pluripotent stem cell trial for Parkinson’s to be approved and conducted in Europe. 👥 The Participants: Eight patients took part in this Phase 1/2 open-label trial, receiving the transplanted cells at two different doses alongside 12 months of immune-suppressing medication to prevent cell rejection. ✅ 100% Safe & Tolerable: The surgical procedure was highly successful and well-tolerated. Crucially, none of the patients developed the involuntary movements that plagued historical cell-transplant attempts decades ago. 📈 The Cells Survived: Specialized PET brain scans at 6 and 12 months showed highly encouraging early signs that the transplanted cells survived and began working. ❤️ Patient Health: Participant health remained stable throughout. While one participant sadly passed away from a lung infection during the study, invest 👉 Read the full story now on Parkinson's Insights @parkinsonsinsights.com Powered by @pdbuddyapp and @nosilverbullet4pd #Parkinsons #parkinsonsresearch #parkinsonsdisease #parkinsonsawareness #Neuroscience